16 Articles in September 2026
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
Overview of the Regulatory Action A recent Food and Drug Administration advisory panel vote has reignited debate over how the agency should regulate the rapidly growing category of therapeutic peptides, according to a report from AJMC (American Journal of Managed Care).
China's Shengnuo Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended
China's Shengnuo Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended The U.S.
Federal regulators and state boards crack down on RUO peptides
Federal and State Regulators Intensify Scrutiny of "Research Use Only" Peptides Federal agencies and state licensing boards are ramping up enforcement against the sale and clinical use of "research use only" (RUO) peptides, a category of compounds that has proliferated in wellness clinics, teleheal...
Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know.
FDA Crackdown on Compounded GLP-1 Drugs Raises Access and Affordability Concerns The Food and Drug Administration's ongoing enforcement actions against compounded versions of popular GLP-1 weight-loss medications are raising new questions about whether millions of Americans will lose access to lowe...
Compounded GLP-1 Crisis: What Patients and Policymakers Need to Know
Overview of the Regulatory Action The compounded GLP-1 receptor agonist controversy represents one of the most consequential pharmaceutical compliance disputes of the past decade, implicating drug shortage law, compounding pharmacy oversight, and consumer safety enforcement simultaneously.
Empower Pharmacy Lawsuit: Updated Sept 2026 Claims
Empower Pharmacy Faces Updated Legal Claims as Litigation Continues Into September 2026 Empower Pharmacy, one of the nation's largest compounding pharmacies and a major supplier of compounded semaglutide, tirzepatide, and other peptide-based therapies, is again in the legal spotlight following repo...
‘Peptide Party’ in Bengaluru cancelled after FDA raises regulatory, safety concerns
‘Peptide Party’ Event in Bengaluru Called Off Amid FDA Scrutiny A gathering billed as a “Peptide Party” scheduled to take place in Bengaluru has been cancelled after regulatory and safety concerns were raised, according to a report from The New Indian Express.
August 17, 2026: Appeals court finds imported medications have “material, not theoretical” differences
Appeals Court Ruling Reinforces Scrutiny of Imported Medications, Citing "Material, Not Theoretical" Risks A federal appeals court has issued a ruling affirming that medications imported from outside the United States can present risks to patients that are "material, not theoretical," according to ...
RFK Says 14 Banned Peptides Are Coming Back Legal. GHK-Cu Is One of Them, But There's a Catch Nobody's Talking About
RFK Jr. Signals Return of 14 Banned Peptides, But Regulatory Fine Print Raises Questions Health and Human Services Secretary Robert F. Kennedy Jr.
The Best FDA Decision On Peptide Authorization Isn’t Yes Or No
The Best FDA Decision On Peptide Authorization Isn't Yes Or No The Food and Drug Administration's approach to regulating therapeutic peptides has reached an inflection point, and according to a recent analysis published by Forbes, the most consequential path forward for the agency may not be a simp...
Phoenix doctor urges caution as FDA moves to regulate popular peptides
Phoenix Doctor Urges Caution as FDA Moves to Regulate Popular Peptides A Phoenix-based physician is warning consumers to exercise caution amid growing regulatory scrutiny of peptide therapies, as the U.S.
FDA issues warning letters to five unapproved GLP-1 websites
FDA Issues Warning Letters to Five Unapproved GLP-1 Websites The U.S. Food and Drug Administration has issued warning letters to five websites for allegedly marketing unapproved versions of GLP-1 receptor agonist products, according to a report from pharmaphorum.com.
FDA cracks down on online black market for weight loss peptides
FDA Targets Illicit Online Sales of Weight Loss Peptides Amid Surging Demand The U.S. Food and Drug Administration is intensifying scrutiny of an expanding online black market for weight loss peptides, according to a report from Pharmaceutical Technology.
Aurobindo Pharma’s Auropeptides US FDA Inspection Ends With One Finding
Aurobindo Pharma's Peptide Manufacturing Unit Clears FDA Inspection With Single Observation Aurobindo Pharma's specialized peptide manufacturing subsidiary, Auropeptides, has concluded a US Food and Drug Administration inspection with only one observation noted, according to a report by Sahi.
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Eli Lilly Files Suit Against Six Firms Over Unauthorized Retatrutide Sales Eli Lilly and Company has filed lawsuits against six companies it accuses of illegally manufacturing, marketing, and selling retatrutide, an experimental obesity and metabolic drug that has not yet received approval from the...
Qatar's Health Ministry bans trading, use or promotion of unlicensed peptide products
Qatar Health Ministry Cracks Down on Unlicensed Peptide Products Qatar's Ministry of Public Health has issued a ban on the trading, use, and promotion of unlicensed peptide products, according to a report from The Peninsula Qatar.